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Biliary stricture in necrotizing pancreatitis (NP) has not been systematically categorized; 
therefore, we sought to define the incidence and natural history of biliary stricture caused by NP. 
Summary/Background Data  
Benign biliary stricture occurs secondary to bile duct injury, anastomotic narrowing, or chronic 
inflammation and fibrosis. The profound loco-regional inflammatory response of NP creates 
challenging biliary strictures. 
Methods: 
NP patients treated between 2005-2019 were reviewed. Biliary stricture was identified on 
cholangiography as narrowing of the extrahepatic biliary tree to <75% of the diameter of the 
unaffected duct. Biliary stricture risk factors and outcomes were evaluated. 
Results: 
Among 743 NP patients, 64 died, 13 were lost to follow up; therefore, a total of 666 patients 
were included in the final cohort. Biliary stricture developed in 108 (16%) patients. Mean follow 
up was 3.5±3.3 years. Median time from NP onset to biliary stricture diagnosis was 4.2 months 
(IQR, 1.8-10.9). Presentation was commonly clinical or biochemical jaundice, n = 30 (28%) 
each. Risk factors for stricture development were splanchnic vein thrombosis and pancreatic 
head parenchymal necrosis. Median time to stricture resolution was 6.0 months after onset (2.8-
9.8). A mean of 3.3±2.3 procedures were performed. Surgical intervention was required in 22 
(20%) patients. Endoscopic treatment failed in 17% (17/99) of patients and was not associated 
with stricture length. Operative treatment of biliary stricture was more likely in patients with 
infected necrosis or NP disease duration ≥6 months. 
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Conclusion: 
Biliary stricture occurs frequently after necrotizing pancreatitis and is associated with splanchnic 
vein thrombosis and pancreatic head necrosis. Surgical correction was performed in 20%. 
Keywords: pancreatitis, acute necrotizing; benign bile duct stricture; splanchnic vein 
thrombosis; choledochostomy; inflammatory stricture 
Mini-Abstract: 
Biliary strictures in necrotizing pancreatitis are challenging to treat and have not been 
systematically categorized. This complication developed in 16% of patients and was associated 
with pancreatic head necrosis and splanchnic vein thrombosis. Endoscopic treatment is effective 
in most; however, 20% of patients underwent operative correction. 
This manuscript includes data that were accepted for presentation at the 2020 annual meetings of 
Digestive Disease Week and the Society for Surgery of the Alimentary Tract in Chicago, IL and 
selected for the Society for Surgery of the Alimentary Tract Residents and Fellows Research 
Conference (TKM).  
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Introduction: 
The morbidity of acute necrotizing pancreatitis (NP) is exceedingly high and mortality 
rates can range from 15-30%1, 2. Common complications in patients with NP include infection, 
organ failure, and pancreatic endocrine and exocrine insufficiency1-5. Long-term sequelae of NP 
are becoming better known and include complications such as disconnected pancreatic duct 
syndrome (DPDS) and splanchnic vein thrombosis (SVT)4, 6-9. Rarely reported are the foregut 
complications from NP, which can involve the stomach and duodenum, bile duct, and pancreatic 
duct. 
Biliary stricture is a well-described complication in 3-21% of chronic pancreatitis (CP) 
patients and can result in life-threatening cholangitis, progressive liver impairment and 
secondary biliary cirrhosis10-13. On the other hand, the true incidence of biliary stricture in acute 
pancreatitis (AP) and its impact on patient outcomes is not known. Case reports and case series 
of NP patients undergoing necrosectomy have described biliary stricture as a complication, but 
this complication has not been systematically characterized in a large cohort of NP patients14-16. 
As such, the ideal treatment strategy and impact on patient outcomes remain unknown.  
Therefore, the aim of this study was to evaluate the incidence of biliary stricture in a 
large cohort of necrotizing pancreatitis patients including risk factors for its development, and 
outcomes. Based on our clinical experience, we hypothesized that biliary stricture in necrotizing 
pancreatitis is more common than previously appreciated and may be difficult to treat 
definitively by endoscopic technique. 
Methods: 
Patient Population 
All patients treated for NP at Indiana University Health University Hospital (IU-UH) 
between January 2005 and June 2019 were included in this study regardless of age, pancreatitis 
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etiology, or treatment strategy. All NP patients are routinely followed long-term by their 
designated pancreatic specialist. Retrospective review of a prospectively maintained institutional 
NP database was performed to identify patients developing biliary stricture after NP. In all 
patients, informed consent was obtained prior to inclusion in the NP database. The Indiana 
University Institutional Review Board approved this study and all data were compiled and stored 
in compliance with the Health Insurance Portability and Accountability Act.  
Parameters Assessed 
In all patients, demographic and clinical information prior to disease onset were recorded 
including age, sex, and medical comorbidities. Clinical information during the course of NP 
included pancreatitis etiology, computed tomography severity index (CTSI), organ failure lasting 
> 48 hours, infected pancreatic necrosis, necrosis intervention (medical, percutaneous,
endoscopic, and surgical), SVT, DPDS, and disease duration. In patients developing biliary 
stricture, the treatment strategy, number of interventions, and time to stricture resolution were 
recorded. 
Definitions 
Diagnostic criteria were defined according to the 2012 revision of the Atlanta 
classification3. Acute pancreatitis (AP) was defined as the presence of at least two of the 
following three criteria: abdominal pain characteristic of AP, serum amylase or lipase 
concentration at least three times greater than the upper limit of normal, or characteristic findings 
of AP on contrast-enhanced cross-sectional imaging. Necrotizing pancreatitis was defined as a 
lack of enhancement of the pancreatic parenchyma on contrast-enhanced cross-sectional imaging 
or the presence of an acute necrotic collection (ANC) or walled-off necrosis (WON)3. Infected 
pancreatic necrosis was diagnosed in the setting of extraluminal gas in the pancreatic and/or 
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peripancreatic tissues on cross-sectional imaging and confirmed with positive bacteria and/or 
fungi on Gram stain and culture of aseptically obtained pancreatic necrosis specimens3. 
Minimally invasive necrosis intervention included percutaneous drainage, endoscopic 
drainage/debridement, videoscopic assisted retroperitoneal debridement (VARD), or 
laparoscopic debridement.  
Per the revised Atlanta classification recommendations, organ failure was defined 
according to the modified Marshall scoring system for organ dysfunction as a score of two or 
greater3. Splanchnic vein thrombosis included thrombosis of the portal vein, superior mesenteric 
vein, and/or splenic vein and was diagnosed by contrast-enhanced cross-sectional imaging as a 
filling defect within the lumen of the vessel or non-visualization of the vein with demonstration 
of multiple collateral veins8. Disconnected pancreatic duct syndrome (DPDS) was diagnosed 
when necrosis involved at least two centimeters of the pancreas with viable upstream (left-sided) 
pancreatic parenchyma and extravasation of contrast or total cutoff of the main pancreatic duct 
on pancreatography17, 18.  
Biliary stricture was diagnosed by magnetic resonance (MRC) or endoscopic retrograde 
(ERC) cholangiography as any narrowing of the biliary tree to less than 75% of the diameter of 
the unaffected duct in the setting of abnormal liver function tests19. This definition was utilized 
during the entire time period of the study by our interventional gastroenterologists and is 
consistent with previous institutional randomized controlled trials evaluating biliary stricture19. 
Cases of clear external compression of the bile duct by pancreatic necrosis were not considered 
as biliary stricture. Stricture resolution was achieved when the affected bile duct diameter was 
confirmed to be 75% or more of the duct above and below the site of the stricture on 
cholangiogram and without subsequent reintervention over a six month period19. 
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Acute NP disease resolution was defined as the absence of clinical symptoms attributable 
to pancreatic necrosis in the setting of radiographic resolution of pancreatic necrosis without 
recurrence of necrotic collections during long-term follow up. 
Statistical Analysis 
Categorical data are described as number with percentage and were compared using the 
chi-squared test. Normally distributed continuous data are reported as mean with standard 
deviation (SD) and were compared using independent samples t-test. Non-normally distributed 
continuous data are reported as median with interquartile range (IQR) and were compared using 
the Mann-Whitney U test. Odds ratios are reported with 95% confidence intervals (95% CI). P-
values < 0.05 were accepted as statistically significant. Univariate analysis was used to identify 
significant risk factors for biliary stricture development. Multivariable binary regression analysis 
was used to confirm these risk factors and included evaluation of any variables with P < 0.1 on 
univariate analysis. Statistical analysis was performed using IBMM SPSS version 26.0 (IBM, 
Inc., Armonk, NY, USA). 
Results: 
Study Population 
A total of 743 NP patients were treated at IU-UH during the study period. Biliary 
etiology (n = 354, 48%) was the most common cause of pancreatitis followed by alcohol (n = 
165, 22%), post-ERCP (n = 44, 6%) and hypertriglyceridemia (n = 43, 6%); pancreatitis was 
idiopathic in 113 (15%) patients. Twenty-three patients developed pancreatitis from less 
common etiologies including medication (n = 16), pancreas divisum (n = 5), pancreatic ductal 
adenocarcinoma (n = 1), hypercalcemia (n = 1), and mucinous cystadenoma (n = 1). The mean 
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age at pancreatitis onset was 52±16 years and 484 (65%) patients were male. The median NP 
disease duration was 5.1 (3.3-8.1) months. Sixty-four (9%) patients died from NP and 13 (2%) 
patients were lost to long-term follow-up; the remaining 666 (89%) patients were followed long-
term for a median of 38 (11-77) months.  
Incidence, Presentation, and Morphology 
Of these 666 NP patients, biliary stricture developed in 108 (16%) patients a median of 
4.2 (1.8-10.9) months after NP onset. Twenty-seven (25%) of these patients developed biliary 
stricture greater than one year after NP onset. The presentation of biliary stricture in NP was 
most often clinical jaundice (n = 30, 28%) or biochemical jaundice (n = 30, 28%); other clinical 
presentations included biliary ductal dilation on routine follow-up imaging (n = 29, 27%), 
abdominal pain (n = 15, 14%), and cholangitis (n = 4, 4%). In patients with biliary stricture 
identified incidentally on imaging, subsequent serum testing revealed abnormal liver chemistry 
in 11 (38%) patients including elevated alkaline phosphatase in seven patients, both elevated 
alkaline phosphatase and total bilirubin in three patients, and elevated total bilirubin in one 
patient. All patients developed stricture in the distal common bile duct. The median stricture 
length was 1.0 (0.5-1.5) centimeters. The median total bilirubin and alkaline phosphatase at 
diagnosis was 1.8 (0.7-6.6) mg/dL and 411 (139-661) U/L, respectively.   
Risk Factors 
Baseline risk factors for biliary stricture development on univariate analysis included 
male sex and history of atrial fibrillation, Table 1. Risk factors during the clinical course of NP 
included infected pancreatic necrosis, SVT, pancreatic head necrosis, and longer disease 
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duration. On multivariable analysis atrial fibrillation (OR, 2.55), SVT (OR, 2.25), and pancreatic 
head necrosis (OR, 1.54) remained significant risk factors. Odds ratios and 95% confidence 
intervals for these risk factors are shown in Figure 1. All patterns of SVT were associated with 
biliary stricture development, even isolated splenic vein thrombosis (Table 2).  
In the 123 patients who did not require pancreatic necrosis intervention, biliary stricture 
developed in eight (7%) patients. Among the 543 patients who underwent necrosis intervention, 
biliary stricture developed in 100 (18%) patients. The increased incidence of biliary stricture 
among patients who underwent intervention was statistically significant (P = 0.004). Biliary 
stricture rates were highest among those patients who underwent a combination of minimally 
invasive and surgical necrosis intervention, Figure 2. When comparing patients whose necrosis 
was treated successfully with minimally invasive intervention only (N = 241) to patients 
resolving with surgical intervention only (N = 120) no difference in the rate of biliary stricture 
was observed (18% vs. 15%, p = 0.4).   
Treatment 
Among the 108 NP patients developing biliary stricture, 106 (98%) patients had 
intervention. The median time to stricture resolution was 6.0 (2.8-9.8) months. Biliary stricture 
resolved after a mean of 3.4±2.3 procedures. A summary of the treatment to achieve definitive 
biliary stricture resolution is shown in Figure 3. Surgical intervention was performed in 22 (20%) 
patients. Three patients underwent surgical intervention as the first step in therapy. In the 
remaining patients, surgery was performed after initial endoscopic (n = 17) or percutaneous (n = 
2) management of biliary stricture; surgery was performed after a median of 7.0 (2.0-10.5)
months of biliary stenting. Endoscopic therapy was successful in 83% of patients; the median 
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duration of endobiliary stenting was 5.8 (2.9-8.6) months. Unsuccessful endoscopic therapy was 
not associated with stricture length (Success, 1.3±0.9 cm; Failure, 1.0±0.6 cm; P = 0.2). Surgical 
intervention was performed with similar rates in patients with biliary stricture that developed 
within one year of NP onset (18 of 81, 22%) when compared to patients with biliary stricture that 
developed greater than one year after NP onset (4 of 27, 15%), p = 0.4.  A greater likelihood of 
unsuccessful endoscopic therapy requiring surgery was observed in patients with a history of 
infected necrosis (OR, 3.2; 95% CI, 1.1-9.0; P = 0.02) or NP disease duration ≥6 months (OR, 
5.7; 95% CI, 1.8-18.2; P = 0.002). Treatment for biliary stricture resulted in inpatient hospital 
admission in 43 (40%) patients for a mean of 13±11 total days. Prior to stricture resolution, 
twenty-eight patients were admitted one time, 13 patients were admitted twice, and 2 patients 
were admitted three times. One patient died prior to any biliary stricture intervention and one 
patient deferred treatment altogether; in these two patients biliary stricture was diagnosed 
incidentally on surveillance imaging. The median follow-up time after biliary stricture resolution 
was 16 (5-51) months. 
Postoperative Outcomes 
A total of 22 patients underwent surgical intervention for biliary stricture. Nine (41%) 
patients underwent choledochoduodenostomy, seven (32%) patients underwent 
hepaticojejunostomy, four (18%) patients underwent pancreatoduodenectomy, and two (9%) 
patients underwent choledochojejunostomy. The median postoperative length of stay was 9 days 
(7-16 days). Five (23%) patients developed a postoperative complication including surgical site 
infection (N = 3), acute cholangitis (N = 1), and bile leak requiring reoperation and redo 
choledochojejunostomy (N = 1). Four (18%) patients required hospital readmission 
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postoperatively. No patients died in the immediate postoperative period and no patient who 
underwent surgical intervention of biliary stricture developed recurrent stricture.  
Discussion: 
In this series of 743 NP patients treated at a single, academic institution, biliary stricture 
developed in 16% of patients surviving acute NP and was diagnosed a median of 4 months after 
NP onset. Risk factors for biliary stricture in NP included male sex, atrial fibrillation, infected 
pancreatic necrosis, splanchnic vein thrombosis, pancreatic head necrosis, and NP duration of six 
months or longer. Independent risk factors were atrial fibrillation, SVT, and pancreatic head 
necrosis. Most patients (74%) were treated successfully and durably by endoscopic technique 
and these patients underwent a mean of 3.4 procedures to achieve stricture resolution over a 
period of six months. Surgical correction was required in 20% of patients with biliary stricture. 
Predictors of unsuccessful endoscopic therapy included patients with a history of infected 
necrosis or NP disease duration of six months or longer. 
Biliary stricture is a known complication of chronic pancreatitis and occurs in 3-21% of 
CP patients in large series10, 11; however, the incidence of biliary stricture in NP patients to date 
has not been systematically described. Only one moderate sized study has reported the incidence 
of biliary stricture to be 6% of 141 AP patients with a fluid collection16. In this series, biliary 
stricture was diagnosed a median of 150 days after AP onset16, similar to our experience. In this 
study by Sugimoto et al. the incidence of biliary stricture was highest in patients with 
disconnected pancreatic duct syndrome (19%)16. We report an incidence of biliary stricture in NP 
patients of 16%, higher than previously appreciated and more similar to the incidence observed 
in CP. As a similar parallel to CP patients10, 20, the presentation of biliary stricture in NP was 
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most often jaundice (biochemical or clinical) and the morphology not surprisingly involved the 
distal common bile duct. It is noteworthy that 27% of NP patients in the current series were 
identified to have “incidental” biliary ductal dilation on imaging during the follow-up period of 
NP, a phenomenon seen in up to 17% of patients with CP20. In this setting, Kalvaria et al 
reported that elevated alkaline phosphatase is more common than elevated bilirubin20, a finding 
also observed in the current series of NP patients with incidental biliary stricture diagnosed on 
follow-up imaging.  
The timing of biliary stricture diagnosis was a median of 4 months after NP onset, a time 
during which most NP patients have active imaging surveillance. The timing of biliary stricture 
in NP in this series corroborates the timeline reported previously by Sugimoto et al16. The 
majority of patients developed biliary stricture within the first year after NP onset, yet, one in 
four patients developed biliary stricture greater than one year after NP onset. The latter point 
highlights the importance of long-term follow-up to which not only biliary stricture, but other, 
often initially subtle long-term problems may arise in this complex group of patients. 
In their descriptive report of biliary stricture in AP, Sugimoto et al reported the incidence 
of biliary stricture was highest among patients with DPDS (19%) with 27% of a subset of 
patients with DPDS involving the head/neck of the pancreas developing biliary stricture16. 
Associated risk factors help provide insight as to potential pathophysiologic mechanisms of 
biliary stricture development in NP. While our study did not find an association with DPDS and 
biliary stricture, pancreatic necrosis located in the head of the pancreas was identified as an 
independent risk factor. In the current study, infected necrosis and longer NP disease duration 
were also associated with biliary stricture. These findings suggest that the location (head of 
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pancreas), severity (infected necrosis), and duration of inflammation (prolonged disease course) 
all play a role in biliary stricture development in NP patients.  
Furthermore, an interesting observation is that patients that underwent both minimally 
invasive intervention and surgical intervention developed biliary stricture with the highest 
frequency. One may speculate that more rapid necrosis evacuation and removal of the 
inflammatory focus may decrease locoregional inflammation, thereby attenuating biliary stricture 
development. Supporting this thesis is the increased incidence of biliary stricture observed in NP 
patients with acute disease lasting longer than six months. On the other hand, patients 
undergoing both minimally invasive and surgical intervention of necrosis suggests that more 
severe disease contributes to a higher incidence of biliary stricture. The hypothesis that 
prolonged locoregional inflammation predisposes to biliary stricture requires more robust study 
to determine its impact but may have important clinical implications that would promote more 
aggressive necrosis evacuation once intervention has been initiated. 
Splanchnic vein thrombosis was independently associated with biliary stricture 
development in this study. It is possible the development of SVT may simply be a surrogate for 
the degree of locoregional inflammation, as regional pancreatic necrosis has been previously 
associated with SVT21. However, impaired venous outflow may impact the blood supply to the 
common bile duct and contribute to biliary stricture development by an ischemic mechanism. It 
may also be possible that common bile duct ischemia develops at a microvascular level in NP 
patients. Endothelial dysfunction and hypercoagulability are known to be associated with severe 
acute pancreatitis and microcirculatory dysfunction plays an important role in the development 
of NP22-27. The locoregional and systemic inflammation in NP may result in a hypercoagulable 
state, microvascular thrombosis, relative bile duct ischemia, and eventual biliary stricture. 
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Favoring this theory over venous outflow obstruction is the observation that all patterns of SVT, 
including isolated splenic vein thrombosis, were associated with biliary stricture development. 
Isolated splenic vein thrombosis does not impact biliary venous outflow and instead may reflect 
the impact of NP on local and systemic inflammation and coagulation.  
The ideal treatment strategy for biliary stricture in NP is unknown; however, principles in 
treating benign biliary strictures can be applied to this clinical scenario. In this series, endoscopic 
stenting of biliary strictures in NP was the first line treatment in 92% of patients and achieved 
definitive resolution in 83%. This success rate is comparable to endoscopic treatment of 
postoperative biliary strictures (80-90%)28, 29 and substantially greater than that achieved in the 
setting of chronic pancreatitis (50-70%)29. The number of procedures (3.4 per patient) and the 
duration of endobiliary stenting (6 months) were similar to that observed in the treatment of 
benign biliary stricture. Predictors of unsuccessful endoscopic treatment requiring operative 
correction included NP disease duration greater than 6 months or a history of infected necrosis. 
Therefore, patients with these clinical factors may be considered for earlier operative 
intervention. 
The retrospective nature of this study limits its ability to identify the pathophysiologic 
mechanisms that result in biliary stricture in NP patients and the proposed mechanisms 
hypothesized in this study clearly warrant further investigation. The independent association 
between atrial fibrillation and biliary stricture may be phenomenological or could represent a 
surrogate for coexisting vascular pathology predisposing patients to ischemic biliary stricture; 
however, the number of patients with atrial fibrillation in this study precluded an in-depth 
subgroup analysis. Clear cases of external bile duct compression by necrosis were not considered 
as biliary stricture; however, it is possible that external compression of the bile duct by necrosis 
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could result in misdiagnosis as biliary stricture, falsely increasing the incidence of biliary 
stricture reported in this study. On the other hand, serial liver function tests during follow up to 
detect biliary stricture development were not routinely evaluated in this study and may 
underestimate the true incidence of biliary stricture after NP. Additionally, patients who died or 
were lost to long-term follow up were not evaluated for biliary stricture. A significant strength of 
this study is its size, which provides benchmark data that have not been previously 
systematically described for biliary stricture in NP, its natural history, treatment, and patient 
outcomes.  
The findings in this study have resulted in a number of changes to the long-term follow 
up of NP survivors at our institution. Given a number of potential sequelae of NP that may 
develop years after acute disease resolution, all NP patients are followed long-term by the 
responsible pancreatologist (pancreatic surgeon and/or gastroenterologist)30. In the first few 
years after NP disease resolution, patients now undergo serial serum evaluation of liver function 
tests at intervals of 3-6 months to screen for biliary stricture development. This practice is 
important to continue at 6-12 month intervals during long-term follow-up, as 25% of patients 
developed biliary stricture beyond one year after NP diagnosis. Early detection and treatment of 
biliary stricture after NP may prevent life-threatening complications such as acute cholangitis or 
secondary biliary cirrhosis.  
Endoscopic biliary stenting is the first line treatment in all NP patients with biliary 
stricture. Patients with a history of infected necrosis or NP lasting greater than six months are 
counseled regarding the decreased likelihood of success with endoscopic treatment alone. 
Operative correction becomes a consideration after six months of attempted endoscopic 
treatment and is determined on a case-by-case basis with multidisciplinary input. In patients with 
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a history of infected necrosis or prolonged disease, operative intervention is considered earlier. 
The ideal treatment strategy for NP patients with normal serum liver function tests and biliary 
stricture diagnosed incidentally on surveillance imaging remains an unanswered question. In this 
setting with chronic pancreatitis patients, the decision to intervene or observe with serial liver 
function tests remains an area of debate10. 
 
Conclusion: 
Biliary stricture occurs frequently after necrotizing pancreatitis and is associated with 
splanchnic vein thrombosis and pancreatic head necrosis. Surgical correction was performed in 
20% and is more likely to be necessary in patients with a history of infected necrosis or 
necrotizing pancreatitis lasting greater than six months. Endoscopic treatment of biliary strictures 
from necrotizing pancreatitis is successful in the majority of patients. 
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Figure Legend: 
Figure 1. Independent risk factors for biliary stricture identified on multivariable analysis and 
associated odds ratios with 95% confidence intervals. 
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Figure 2. The incidence of biliary stricture was lowest among patients that did not require 
necrosis intervention and highest among those requiring a combination of minimally invasive 
and surgical necrosis intervention, P = 0.001.  
Footnote: Minimally invasive necrosis intervention includes percutaneous drainage, endoscopic 
drainage/debridement, videoscopic assisted retroperitoneal debridement, or laparoscopic 
debridement. Abbreviations: NP – necrotizing pancreatitis 
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Figure 3. Summary of Intervention to Achieve Biliary Stricture Resolution 
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Table 1. Univariate and multivariable analysis comparing demographic and clinical variables 
between patients without biliary stricture (Control) and patients with biliary stricture after 
necrotizing pancreatitis. 
Risk Factor 
Control (n = 
558) 
n, (%) 









Pancreatitis Etiology   0.6 ----- 
Biliary 265 (47) 60 (56)   
Alcohol 129 (23) 19 (18)   
Triglyceride 32 (2) 7 (6)   
Post-ERCP 32 (6) 6 (6)   
Idiopathic/Other 100 (18) 16 (15)   
Age, Years* 50.6±15.6 52.8±15.3 0.2 ----- 
Male Sex 353 (63) 79 (73) 0.049 0.2 
Alcohol Abuse 91 (16) 17 (16) 0.9 ----- 
Asthma 28 (5) 4 (4) 0.6 ----- 
Atrial Fibrillation 17 (3) 9 (8) 0.01 0.03 
Coronary Artery Disease 59 (11) 12 (11) 0.9 ----- 
Chronic Kidney Disease 17 (3) 1 (1) 0.2 ----- 
COPD 43 (8) 7 (6) 0.7 ----- 
CVA/TIA 17 (3) 7 (6) 0.08 0.2 
Diabetes Mellitus 141 (25) 34 (31) 0.2 ----- 
Hyperlipidemia 184 (33) 40 (37) 0.4 ----- 
Hypertension 321 (58) 65 (60) 0.6 ----- 
Obesity 266 (48) 53 (49) 0.8 ----- 
Tobacco Use 232 (42) 43 (40) 0.8 ----- 
Infected Necrosis 224 (40) 55 (51) 0.04 0.1 
Any organ failure 195 (35) 37 (34) 0.9 ----- 
Respiratory  156 (28) 34 (31) 0.5 ----- 
Renal  99 (18) 24 (22) 0.3 ----- 
Cardiovascular  53 (9) 12 (11) 0.6 ----- 
DPDS 263 (47) 52 (48) 0.9 ----- 
Splanchnic Vein 
Thrombosis 
222 (40) 69 (64) 0.00001 0.001 
Pancreatic Head 
Necrosis 
221 (40) 58 (54) 0.007 0.045 
CT Severity Index* 6.6±2.0 7.0±2.0 0.05 0.9 
NP Duration, Days** 150 (93-233) 186 (112-278) 0.005 0.1 
NP Duration >6 Months 218 (39) 58 (54) 0.005 0.5 
Abbreviations: ERCP- endoscopic retrograde cholangiopancreatography; COPD – chronic 
obstructive pulmonary disease; CVA – cerebrovascular accident; TIA – transient ischemic 
attack; DPDS – disconnected pancreatic duct syndrome; CT – computed tomography; NP – 
necrotizing pancreatitis 
*Mean values (± standard deviation) compared using independent groups t-test. 
**Median values (with interquartile range) compared using the Mann-Whitney U test. 
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Table 2. Incidence of biliary stricture among different patterns of splanchnic vein thrombosis. 
Splanchnic Vein Thrombosis 
Control 
(n = 558) 
n, (%) 
Biliary Stricture 




Superior Mesenteric Vein† 
Portal and/or Superior Mesenteric Veins 













†Either alone or in combination with another splanchnic vein 
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